Nanthapisal, S; Murphy, C; Omoyinmi, E; Hong, Y; Standing, A; Gilmour, K; Berg, S; ... Brogan, P; + view all Nanthapisal, S; Murphy, C; Omoyinmi, E; Hong, Y; Standing, A; Gilmour, K; Berg, S; Ekelund, M; Jolles, S; Harper, L; Youngstein, T; Klein, N; Eleftheriou, D; Brogan, P; - view fewer (2016) Deficiency of adenosine deaminase type 2 (DADA2): a description of phenotype and genotype in 15 cases. Arthritis and Rheumatology , 68 (9) pp. 2314-2322. 10.1002/art.39699.

Preview	Text Nanthapisal_CECR1 manuscript 2nd revision_final proof_cleaned.pdf Download (359kB) | Preview
Preview	Text Nanthapisal_SUPPLEMENTARY 131015.pdf Download (232kB) | Preview
Preview	Image Nanthapisal_Figure 1 - 131015 300.tif Download (1MB) | Preview
Preview	Image Nanthapisal_Figure 2 -010216 300.tif Download (1MB) | Preview

Abstract

OBJECTIVES: To describe the clinical features, genotype, and treatment of a series of subjects with confirmed Deficiency of Adenosine Deaminase 2 (DADA2) referred to Great Ormond Street Hospital NHS Foundation Trust (GOSH), London. / METHODS: All symptomatic subjects were referred for genetic testing for suspected DADA2; relatives of index cases were also screened. The demographic, clinical, laboratory characteristics and treatments were recorded. Genetic analyses performed included whole-exome sequencing in 4 patients; and Sanger sequencing of Cat Eye Syndrome Chromosome Region Candidate 1 (CECR1) in all subjects. ADA2 enzyme activity assay, and quantitative PCR of CECR1 mRNA were also performed. / RESULTS: We identified 15 subjects with DADA2; 5 subjects were asymptomatic (relatives of index cases; age 5-42 years). Homozygous or compound heterozygous mutations in CECR1 were identified in all subjects. The phenotypic manifestations of the symptomatic DADA2 patients included livedo racemosa (73.3%); neurologic involvement (53.3%); and immune deficiency (46.6%). CECR1 mRNA expression in 8 subjects, including five pre-symptomatic subjects was significantly lower than healthy controls (p=0.0016). DADA2 subjects (with or without symptoms) also had lower ADA2 enzyme activity compared to healthy paediatric controls (p<0.0001), and sporadic cases of childhood polyarteritis nodosa without CECR1 mutation (p=0.0108). Nine/10 symptomatic patients required anti-TNF-α therapy. / CONCLUSION: The clinical severity of DADA2 ranged from limited cutaneous to severe multi-systemic vasculitis; one third (5/15) of our cases were currently asymptomatic, and required close monitoring. We recommend CECR1 screening for: unaffected siblings of index cases; cases of familial vasculitis; and patients with polyarteritis nodosa recalcitrant to standard treatment.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item